|By PR Newswire||
|August 7, 2014 02:54 PM EDT||
MIAMI, Aug. 7, 2014 /PRNewswire/ -- NextSource Biotechnology (NSB) is a leading specialty pharmaceutical manufacturer with a focus on identifying and developing the most viable pipeline of "matured" and "innovative drugs" in today's global healthcare market.
The product name change from Lomustine (CCNU) to GleostineTM represents the company's strategic initiative to re-launch and re-brand its product pipeline of matured and innovative drugs. The new GleostineTM product labeling will be visible in the healthcare market by the fourth quarter of 2014. Lomustine is currently available through all payer organizations nationwide – including both commercial and government providers of prescription drug coverage.
GleostineTM is a sole source FDA approved product, which is also accessible through NextSource CARES, NSB's patient assistance program. As a result of the company's extensive market access efforts, the continued use of unregulated compounded products or any other unapproved versions of GleostineTM, will continue to present an unnecessary risk to both healthcare providers and patients. NextSource Biotechnology is committed to providing the highest quality product with a consistent market supply.
"The re-branding of GleostineTM," said Robert DiCrisci, President, CEO of NextSource Biotechnology, "is the first of many product launches to come. As this initiative continues, we will expand our product line to ensure consistent availability to patients with critical medical need."
About NextSource Biotechnology: Established in 2010, NextSource Biotechnology is a leading specialty pharmaceutical manufacturer with a focus on identifying and developing the most viable pipeline of "Matured" and "Innovative drugs" in today's global healthcare market. NextSource partner, CordenPharma Latina is an expert contract manufacturer helping leading pharmaceutical and Biotechnology companies link their requirements for product success with their patients' healthier lives.
SOURCE NextSource Biotechnology
In his general session at 18th Cloud Expo, Lee Atchison, Principal Cloud Architect and Advocate at New Relic, discussed cloud as a ‘better data center’ and how it adds new capacity (faster) and improves application availability (redundancy). The cloud is a ‘Dynamic Tool for Dynamic Apps’ and resource allocation is an integral part of your application architecture, so use only the resources you need and allocate /de-allocate resources on the fly.
Sep. 27, 2016 05:15 PM EDT Reads: 2,749
If you had a chance to enter on the ground level of the largest e-commerce market in the world – would you? China is the world’s most populated country with the second largest economy and the world’s fastest growing market. It is estimated that by 2018 the Chinese market will be reaching over $30 billion in gaming revenue alone. Admittedly for a foreign company, doing business in China can be challenging. Often changing laws, administrative regulations and the often inscrutable Chinese Interne...
Sep. 27, 2016 05:15 PM EDT Reads: 264
Enterprise IT has been in the era of Hybrid Cloud for some time now. But it seems most conversations about Hybrid are focused on integrating AWS, Microsoft Azure, or Google ECM into existing on-premises systems. Where is all the Private Cloud? What do technology providers need to do to make their offerings more compelling? How should enterprise IT executives and buyers define their focus, needs, and roadmap, and communicate that clearly to the providers?
Sep. 27, 2016 05:00 PM EDT Reads: 1,587
Sep. 27, 2016 04:45 PM EDT Reads: 349
Sep. 27, 2016 04:00 PM EDT Reads: 2,639
Sep. 27, 2016 03:30 PM EDT Reads: 301
Sep. 27, 2016 03:15 PM EDT Reads: 2,856
Sep. 27, 2016 03:15 PM EDT Reads: 2,757
Sep. 27, 2016 03:15 PM EDT Reads: 1,367
Sep. 27, 2016 03:00 PM EDT Reads: 1,689
Sep. 27, 2016 02:45 PM EDT Reads: 1,259
Sep. 27, 2016 02:45 PM EDT Reads: 2,202
Sep. 27, 2016 02:45 PM EDT Reads: 4,640
Sep. 27, 2016 02:15 PM EDT Reads: 1,996
Sep. 27, 2016 02:00 PM EDT Reads: 1,445